Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 27, 2026

Crypto Allocations by Financial Advisors Hit All-Time High in 2025

View original at finance.yahoo.com
Crypto Allocations by Financial Advisors Hit All-Time High in 2025 Broadcast Retirement Network's Jeffrey Snyder discusses the shifting cryptocurrency landscape with Bitwise Asset Management's Matthew Hougan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 30 to 40 percent of financial advisors are now using crypto in client accounts

    80% confidence
  • If I had to sum up 2025 in one word, it would be mainstream

    80% confidence
  • Regulatory uncertainty was the number one blocker preventing advisors from entering crypto market for the last eight years

    80% confidence
  • Passage of the Clarity Act would be very good for the crypto market

    80% confidence
  • Bitcoin is about as volatile as large cap AI stocks like Nvidia

    80% confidence
  • Largest financial professionals are increasingly treating crypto as just another asset class alongside stocks, bonds and commodities

    80% confidence
  • Crypto has become a normal and increasingly important part of global financial infrastructure

    80% confidence
  • Crypto has been one of the fastest growing industries in the world over the last decade and is accelerating in the new regulatory environment

    80% confidence
  • 2025 is the year that crypto really started to go mainstream

    80% confidence
  • The crypto industry has evolved to become more institutional, regulated, and safe

    80% confidence
  • 99 percent of advisors who owned crypto in 2024 plan to either maintain or add to their exposure in 2026

    80% confidence
  • The outlook is very bright for crypto in 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Crypto Allocations by Financial Advisors Hit All-Time High in 2025 — Source | Via News | ViaNews EU